US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARS PHARMACEUTICALS INC

9.96

+0.17001.74%

Volume:368.33K

Turnover:3.66M

Market Cap:984.53M

PE:-12.21

High:10.11

Open:9.81

Low:9.78

Close:9.79

52wk High:18.90

52wk Low:6.66

Shares:98.85M

Float Shares:55.27M

Volume Ratio:0.44

T/O Rate:0.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8154

EPS(LYR):0.0800

ROE:-45.92%

ROA:-19.22%

PB:6.67

PE(LYR):124.50

Loading ...

Overview Company News Filings

ARS Pharmaceuticals Unveils New Clinical Data Highlighting neffy Nasal Epinephrine Advantages

EU Panel Recommends Approval of ARS Pharma’s EURneffy 1 mg Nasal Adrenaline Spray for Children

Eurneffy® 1 Mg (Adrenaline Nasal Spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, Including Anaphylaxis in Children Weighing ≥15 Kg to <30 Kg

THOMSON REUTERS

EU Regulators Recommend Approval of ALK-Abelló's EURneffy 1 mg Nasal Spray for Pediatric Anaphylaxis

ARS Pharmaceuticals announces California eligible for neffyinSchools program

ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application

Benzinga_recent_news

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy

Simply Wall St.

China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product

ARS Pharmaceuticals Inc - to Supply Neffy in China by Spring 2026

THOMSON REUTERS

ARS Pharmaceuticals - to Receive $4 Mln Regulatory Milestone and Is Eligible to Receive up to $80 Mln in Sales Milestones

THOMSON REUTERS

Neffy® (Epinephrine Nasal Spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)

THOMSON REUTERS

ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares

ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28

THOMSON REUTERS

Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses

Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss

MT Newswires Live

ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate

ARS Pharmaceuticals Q3 Net Income USD -51.151 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":9.96,"timestamp":1770752265332,"preClose":9.79,"halted":0,"volume":368328,"delay":0,"changeRate":0.017364657814096192,"floatShares":55270496,"shares":98848611,"eps":-0.81541,"marketStatus":"Trading","change":0.17,"latestTime":"02-10 14:37:49 EST","open":9.81,"high":10.11,"low":9.78,"amount":3656395.0026240004,"amplitude":0.033708,"askPrice":9.97,"askSize":60,"bidPrice":9.94,"bidSize":726,"shortable":3,"etf":0,"ttmEps":-0.81541,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":9.79,"preHourTrading":{"tag":"盘前","latestPrice":9.88,"preClose":9.79,"latestTime":"08:54 EST","volume":93,"amount":920.339997,"timestamp":1770731658446,"change":0.09,"changeRate":0.009193,"amplitude":0.015322},"postHourTrading":{"tag":"盘后","latestPrice":9.8,"preClose":9.79,"latestTime":"17:01 EST","volume":20823,"amount":203811.95,"timestamp":1770674490515,"change":0.01,"changeRate":0.001021,"amplitude":0.02145},"volumeRatio":0.43928,"impliedVol":0.2623,"impliedVolPercentile":0.012},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":55270496,"roa":"-19.22%","roe":"-45.92%","lyrEps":0.079999,"volumeRatio":0.43928,"shares":98848611,"dividePrice":0,"high":10.11,"amplitude":0.033708,"preClose":9.79,"low":9.78,"week52Low":6.66,"pbRate":"6.67","psRate":"6.90","week52High":18.9,"institutionHeld":0,"latestPrice":9.96,"committee":0.847328,"eps":-0.81541,"divideRate":0,"volume":368328,"delay":0,"ttmEps":-0.81541,"open":9.81,"prevYearClose":11.65,"prevWeekClose":10.03,"prevMonthClose":9.99,"prevQuarterClose":11.65,"fiveDayClose":10.15,"twentyDayClose":11.38,"sixtyDayClose":8.945},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"SPRY","fiscalQuarterEnding":"2025/09","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2025-08-13","symbol":"SPRY","fiscalQuarterEnding":"2025/06","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2025-05-14","symbol":"SPRY","fiscalQuarterEnding":"2025/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1762491600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2026-02-09","current":-12.214714,"percent":0.790013,"low":-115.157754,"twenty":-29.999267,"median":-18.031385,"eighty":-12.275913,"high":184.020638,"avg":-17.013122,"sd":47.885102,"marketCap":991451568},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.313866,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":860429873},{"date":"2024-06-07","current":-17.177383,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":853647205},{"date":"2024-06-14","current":-16.884919,"twenty":-27.543213,"median":-15.872834,"eighty":-9.957071,"marketCap":839112916},{"date":"2024-06-21","current":-15.929536,"twenty":-27.026227,"median":-15.872834,"eighty":-9.981995,"marketCap":791634241},{"date":"2024-06-28","current":-16.592455,"twenty":-26.233342,"median":-15.857321,"eighty":-10.038073,"marketCap":824578628},{"date":"2024-07-05","current":-17.742813,"twenty":-26.122559,"median":-15.901185,"eighty":-10.097267,"marketCap":881746829},{"date":"2024-07-12","current":-22.129772,"twenty":-26.004391,"median":-15.977907,"eighty":-10.112844,"marketCap":1099761155},{"date":"2024-07-19","current":-20.550467,"twenty":-25.84191,"median":-16.008119,"eighty":-10.131537,"marketCap":1021275998},{"date":"2024-07-26","current":-21.408361,"twenty":-25.598187,"median":-16.06602,"eighty":-10.234348,"marketCap":1063909910},{"date":"2024-08-02","current":-19.302621,"twenty":-25.251068,"median":-16.155521,"eighty":-10.620668,"marketCap":959263034},{"date":"2024-08-09","current":-23.520911,"twenty":-24.881793,"median":-16.206368,"eighty":-10.941562,"marketCap":1054724705},{"date":"2024-08-16","current":-28.81744,"twenty":-25.84191,"median":-16.286222,"eighty":-11.035026,"marketCap":1292231647},{"date":"2024-08-23","current":-28.017556,"twenty":-27.270827,"median":-16.393243,"eighty":-11.081758,"marketCap":1256363252},{"date":"2024-08-30","current":-28.060793,"twenty":-27.941591,"median":-16.401625,"eighty":-11.197031,"marketCap":1258302084},{"date":"2024-09-06","current":-24.558599,"twenty":-27.79336,"median":-16.442915,"eighty":-11.309188,"marketCap":1101256678},{"date":"2024-09-13","current":-28.752585,"twenty":-27.79336,"median":-16.472628,"eighty":-11.620736,"marketCap":1289323399},{"date":"2024-09-20","current":-31.930502,"twenty":-27.995938,"median":-16.576918,"eighty":-11.620736,"marketCap":1431827564},{"date":"2024-09-27","current":-30.95767,"twenty":-28.060793,"median":-16.631178,"eighty":-11.714201,"marketCap":1388203840},{"date":"2024-10-04","current":-30.67663,"twenty":-28.212122,"median":-16.751589,"eighty":-11.833393,"marketCap":1375601431},{"date":"2024-10-11","current":-31.39004,"twenty":-28.39555,"median":-16.860498,"eighty":-11.83882,"marketCap":1407592162},{"date":"2024-10-18","current":-34.567957,"twenty":-28.752585,"median":-16.884919,"eighty":-11.967761,"marketCap":1550096327},{"date":"2024-10-25","current":-31.930502,"twenty":-28.968769,"median":-17.021402,"eighty":-12.05734,"marketCap":1431827564},{"date":"2024-11-01","current":-32.989808,"twenty":-29.172776,"median":-17.10772,"eighty":-12.236498,"marketCap":1479328953},{"date":"2024-11-08","current":-36.837898,"twenty":-29.53085,"median":-17.177383,"eighty":-12.27233,"marketCap":1651885017},{"date":"2024-11-15","current":-27.728261,"twenty":-29.574087,"median":-17.203935,"eighty":-12.290246,"marketCap":1361568504},{"date":"2024-11-22","current":-27.708469,"twenty":-29.53085,"median":-17.216378,"eighty":-12.329028,"marketCap":1360596650},{"date":"2024-11-29","current":-28.717849,"twenty":-29.510269,"median":-17.294264,"eighty":-12.329028,"marketCap":1410161242},{"date":"2024-12-06","current":-27.748052,"twenty":-29.318167,"median":-17.323614,"eighty":-12.355333,"marketCap":1362540359},{"date":"2024-12-13","current":-23.552198,"twenty":-29.200708,"median":-17.377363,"eighty":-12.390575,"marketCap":1156507152},{"date":"2024-12-20","current":-22.127191,"twenty":-29.174826,"median":-17.429503,"eighty":-12.426406,"marketCap":1086533610},{"date":"2024-12-27","current":-21.355313,"twenty":-29.123341,"median":-17.460097,"eighty":-12.465821,"marketCap":1048631275},{"date":"2025-01-03","current":-22.146983,"twenty":-29.064257,"median":-17.508842,"eighty":-12.501652,"marketCap":1087505465},{"date":"2025-01-10","current":-22.245942,"twenty":-29.025066,"median":-17.556082,"eighty":-12.530317,"marketCap":1092364739},{"date":"2025-01-17","current":-24.878247,"twenty":-29.013807,"median":-17.625827,"eighty":-12.566149,"marketCap":1221621420},{"date":"2025-01-24","current":-27.866803,"twenty":-28.968769,"median":-17.665522,"eighty":-12.594815,"marketCap":1368371488},{"date":"2025-01-31","current":-25.768876,"twenty":-28.968769,"median":-17.692748,"eighty":-12.61273,"marketCap":1265354884},{"date":"2025-02-07","current":-23.591782,"twenty":-28.81744,"median":-17.719962,"eighty":-12.684394,"marketCap":1158450862},{"date":"2025-02-14","current":-23.7897,"twenty":-28.81245,"median":-17.725862,"eighty":-12.70231,"marketCap":1168169409},{"date":"2025-02-21","current":-22.245942,"twenty":-28.80529,"median":-17.742813,"eighty":-12.730975,"marketCap":1092364739},{"date":"2025-02-28","current":-20.741768,"twenty":-28.766646,"median":-17.750677,"eighty":-12.878556,"marketCap":1018503778},{"date":"2025-03-07","current":-21.474063,"twenty":-28.753554,"median":-17.783612,"eighty":-12.988431,"marketCap":1054462403},{"date":"2025-03-14","current":-23.492823,"twenty":-28.724796,"median":-17.918291,"eighty":-13.032048,"marketCap":1153591588},{"date":"2025-03-21","current":151.633005,"twenty":-28.645299,"median":-17.929848,"eighty":-12.988431,"marketCap":1212760777},{"date":"2025-03-28","current":153.227851,"twenty":-28.604711,"median":-17.78435,"eighty":-12.670061,"marketCap":1225516351},{"date":"2025-04-04","current":157.030944,"twenty":-28.551598,"median":-17.756493,"eighty":-12.515985,"marketCap":1255933491},{"date":"2025-04-11","current":172.365997,"twenty":-28.537065,"median":-17.742813,"eighty":-12.355333,"marketCap":1378583246},{"date":"2025-04-17","current":182.548472,"twenty":-28.53527,"median":-17.728408,"eighty":-12.28308,"marketCap":1460022683},{"date":"2025-04-25","current":168.930945,"twenty":-28.478265,"median":-17.719962,"eighty":-11.916185,"marketCap":1351109701},{"date":"2025-05-02","current":177.55989,"twenty":-28.413636,"median":-17.701176,"eighty":-11.620736,"marketCap":1420124003},{"date":"2025-05-09","current":165.034919,"twenty":-28.363303,"median":-17.672598,"eighty":-11.047488,"marketCap":1319949281},{"date":"2025-05-16","current":-85.348526,"twenty":-28.478265,"median":-17.679674,"eighty":-10.985179,"marketCap":1335704429},{"date":"2025-05-23","current":-91.122103,"twenty":-28.610323,"median":-17.701176,"eighty":-11.047488,"marketCap":1426060905},{"date":"2025-05-30","current":-97.209461,"twenty":-28.755493,"median":-17.719962,"eighty":-11.103567,"marketCap":1521328059},{"date":"2025-06-06","current":-84.344425,"twenty":-28.908237,"median":-17.728408,"eighty":-11.22507,"marketCap":1319990259},{"date":"2025-06-13","current":-90.369027,"twenty":-29.139819,"median":-17.742813,"eighty":-11.433807,"marketCap":1414275278},{"date":"2025-06-20","current":-99.845224,"twenty":-29.414401,"median":-17.756493,"eighty":-11.620736,"marketCap":1562577755},{"date":"2025-06-27","current":-113.463334,"twenty":-29.625971,"median":-17.78435,"eighty":-11.639429,"marketCap":1775701182},{"date":"2025-07-03","current":-103.673356,"twenty":-29.970507,"median":-17.918291,"eighty":-11.714201,"marketCap":1622488027},{"date":"2025-07-11","current":-112.835772,"twenty":-30.109473,"median":-17.96922,"eighty":-11.833393,"marketCap":1765879826},{"date":"2025-07-18","current":-115.157754,"twenty":-30.373971,"median":-18.060207,"eighty":-11.83882,"marketCap":1802218844},{"date":"2025-07-25","current":-112.459234,"twenty":-30.612951,"median":-18.156476,"eighty":-11.967761,"marketCap":1759987013},{"date":"2025-08-01","current":-110.953084,"twenty":-30.649879,"median":-18.318793,"eighty":-12.05734,"marketCap":1736415758},{"date":"2025-08-08","current":-110.764815,"twenty":-30.849578,"median":-18.491503,"eighty":-12.236498,"marketCap":1733469351},{"date":"2025-08-15","current":-29.781475,"twenty":-31.056082,"median":-18.779127,"eighty":-12.27233,"marketCap":1430017096},{"date":"2025-09-05","current":-22.001657,"twenty":-31.011769,"median":-19.029654,"eighty":-12.286663,"marketCap":1056453542},{"date":"2025-09-12","current":-20.890254,"twenty":-30.966274,"median":-19.71207,"eighty":-12.321272,"marketCap":1003087320},{"date":"2025-09-19","current":-20.43746,"twenty":-30.871196,"median":-20.12152,"eighty":-12.329028,"marketCap":981345526},{"date":"2025-09-26","current":-19.63478,"twenty":-30.797693,"median":-20.134768,"eighty":-12.355333,"marketCap":942803254},{"date":"2025-10-03","current":-21.157814,"twenty":-30.698248,"median":-20.149319,"eighty":-12.390575,"marketCap":1015934744},{"date":"2025-10-10","current":-23.833413,"twenty":-30.67,"median":-20.178749,"eighty":-12.426406,"marketCap":1144408982},{"date":"2025-10-17","current":-20.807928,"twenty":-30.653572,"median":-20.2775,"eighty":-12.47657,"marketCap":999134267},{"date":"2025-10-24","current":-19.861177,"twenty":-30.649879,"median":-20.299599,"eighty":-12.515985,"marketCap":953674152},{"date":"2025-10-31","current":-17.74128,"twenty":-30.620337,"median":-20.187599,"eighty":-12.551817,"marketCap":851883024},{"date":"2025-11-07","current":-16.866565,"twenty":-30.612951,"median":-20.149319,"eighty":-12.587649,"marketCap":809881831},{"date":"2025-11-14","current":-10.386267,"twenty":-30.612951,"median":-20.12152,"eighty":-12.426406,"marketCap":831316818},{"date":"2025-11-21","current":-8.311484,"twenty":-30.553867,"median":-19.933213,"eighty":-12.321272,"marketCap":665251152},{"date":"2025-11-28","current":-11.781806,"twenty":-30.491905,"median":-19.75827,"eighty":-12.164835,"marketCap":943015748},{"date":"2025-12-05","current":-12.312852,"twenty":-30.408561,"median":-19.63478,"eighty":-11.836649,"marketCap":985520651},{"date":"2025-12-12","current":-13.856589,"twenty":-30.373971,"median":-19.314339,"eighty":-11.916185,"marketCap":1109081415},{"date":"2025-12-19","current":-12.127603,"twenty":-30.309116,"median":-19.029654,"eighty":-12.021508,"marketCap":970693360},{"date":"2025-12-26","current":-14.177687,"twenty":-30.256997,"median":-18.779127,"eighty":-12.085445,"marketCap":1134782054},{"date":"2026-01-02","current":-14.387635,"twenty":-30.230821,"median":-18.672648,"eighty":-12.149382,"marketCap":1151586318},{"date":"2026-01-09","current":-13.523142,"twenty":-30.165419,"median":-18.491503,"eighty":-12.241889,"marketCap":1082392290},{"date":"2026-01-16","current":-13.696041,"twenty":-30.101841,"median":-18.441052,"eighty":-12.263452,"marketCap":1096231095},{"date":"2026-01-23","current":-13.053846,"twenty":-30.071312,"median":-18.318793,"eighty":-12.263452,"marketCap":1044829818},{"date":"2026-01-30","current":-12.621599,"twenty":-30.016829,"median":-18.156476,"eighty":-12.27233,"marketCap":1010232804},{"date":"2026-02-06","current":-11.942355,"twenty":-30.006457,"median":-18.060207,"eighty":-12.27233,"marketCap":955866068},{"date":"2026-02-09","current":-12.386951,"twenty":-29.999267,"median":-18.031385,"eighty":-12.275913,"marketCap":991451568}],"updateTime":1770752269979},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610628315","title":"ARS Pharmaceuticals Unveils New Clinical Data Highlighting neffy Nasal Epinephrine Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=2610628315","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610628315?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728419,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. announced that five poster presentations highlighting new clinical data on neffy  will be showcased at the 2026 American Academy of Allergy, Asthma and Immunology  Annual Scientific Meeting. The presentations will include information on the clinical advancement, real-world usability, and advantages of needle-free epinephrine delivery. The company noted that neffy offers a longer shelf life compared to epinephrine auto-injectors, resulting in a more affordable, value-based price. The results of these studies, including pharmacoeconomic data and patient preference, will be presented at the upcoming meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL6Fj37s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","BK4112","IE00B3QW5Z07.USD","SPRY","BK4588","BK4139"],"gpt_icon":0},{"id":"2608876861","title":"EU Panel Recommends Approval of ARS Pharma’s EURneffy 1 mg Nasal Adrenaline Spray for Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876861","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608876861?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:01","pubTimestamp":1770037281,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the expansion of the marketing authorization for EURneffy to include a 1 mg nasal adrenaline spray. This product is intended for the emergency treatment of allergic reactions, including anaphylaxis, in children weighing between 15 kg and less than 30 kg. Following expected authorization by the European Commission, EURneffy 1 mg will be marketed and distributed in the European Union by ARS Pharma's partner, ALK-Abelló A/S.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNews","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6nv9H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU0314104364.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","NDAQ","SPRY","SG9999014013.SGD","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2608869061","title":"Eurneffy® 1 Mg (Adrenaline Nasal Spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, Including Anaphylaxis in Children Weighing ≥15 Kg to <30 Kg","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869061?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1TBNWF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2607039803","title":"EU Regulators Recommend Approval of ALK-Abelló's EURneffy 1 mg Nasal Spray for Pediatric Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2607039803","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607039803?lang=en_us&edition=fundamental","pubTime":"2026-01-29 23:15","pubTimestamp":1769699734,"startTime":"0","endTime":"0","summary":"ALK-Abelló A/S announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has adopted a positive opinion recommending the granting of marketing authorisation for EURneffy 1 mg, a needle-free nasal adrenaline spray for the emergency treatment of anaphylaxis in children aged 4 years and older with a bodyweight between 15 kg and 30 kg. The CHMP opinion will be reviewed by the European Commission, with a decision on marketing authorisation expected in the coming months. If granted, the authorisation will be valid in all EU member states, as well as Iceland, Liechtenstein, and Norway. EURneffy is developed by ARS Pharmaceuticals, Inc., which has granted ALK exclusive global rights to commercialise the product outside the USA, Australia, New Zealand, Japan, and China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL8TcVjl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","SPRY","BK4139","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2605107172","title":"ARS Pharmaceuticals announces California eligible for neffyinSchools program","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107172?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:10","pubTimestamp":1769001051,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) announced that California is now eligible for its neffyinSchools program. “One year ago, we envisioned a nationwide prog...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-announces-california-eligible-for-neffyinschools-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-announces-california-eligible-for-neffyinschools-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2603253415","title":"ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2603253415","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603253415?lang=en_us&edition=fundamental","pubTime":"2026-01-13 04:16","pubTimestamp":1768248960,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals, Inc.  is currently at $11.36, down $1.70 or 13.02%. --On pace for largest percent decrease since March 21, 2025, when it fell 13.63%. --Down 81.2% from its all-time closing high of $60.41 on March 17, 2021. --Up 0.89% from 52 weeks ago , when it closed at $11.26. --Down 38.09% from its 52-week closing high of $18.35 on July 28, 2025. --Down 14.24% at today's intraday low; largest intraday percent decrease since Aug. 29, 2025, when it fell as much as 14.62%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2602707370","title":"Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2602707370","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602707370?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:28","pubTimestamp":1767976080,"startTime":"0","endTime":"0","summary":"Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/09/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/09/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/49817029/aquestive-stock-slides-after-fda-flags-issues-with-allergy-drug-application","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/49817029/aquestive-stock-slides-after-fda-flags-issues-with-allergy-drug-application","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","SPRY","BK4007","AQST"],"gpt_icon":0},{"id":"2602372459","title":"ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2602372459","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602372459?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:40","pubTimestamp":1767969636,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals’ (SPRY) competitor Aquestive Therapeutics (AQST) received an FDA letter citing NDA deficiencies for Anaphylm, preventing discus...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-competitor-gets-fda-deficiency-letter-says-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-competitor-gets-fda-deficiency-letter-says-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SPRY","IE00BGHQF748.EUR","AQST","BK4139","LU2265009873.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","RJF","BK4127","LU1363072403.SGD","LU1804176565.USD","BK4007","LU0971096721.USD","BK4588"],"gpt_icon":0},{"id":"2595718120","title":"ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595718120","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595718120?lang=en_us&edition=fundamental","pubTime":"2025-12-30 18:26","pubTimestamp":1767090369,"startTime":"0","endTime":"0","summary":"The fact that multiple ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) insiders offloaded a considerable amount of shares...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-spry/ars-pharmaceuticals/news/ars-pharmaceuticals-insiders-sold-us13m-of-shares-suggesting","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-spry/ars-pharmaceuticals/news/ars-pharmaceuticals-insiders-sold-us13m-of-shares-suggesting","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2595802397","title":"China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2595802397","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595802397?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013225,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. announced that its product neffy  has been approved in China as the first and only community use epinephrine product for the treatment of allergic reactions . This approval allows adults and children over 30 kg living with severe allergic reactions to access epinephrine outside of hospital settings for the first time in China. Under an exclusive licensing agreement, Pediatrix Therapeutics holds the rights to commercialize neffy in China and plans to make the product available in the spring of 2026. ARS Pharma will receive a final regulatory milestone payment of $4 million and is eligible for up to $80 million in sales milestones, in addition to tiered royalties on annual net sales.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL7dljB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","SPRY","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","LU0314104364.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2595802567","title":"ARS Pharmaceuticals Inc - to Supply Neffy in China by Spring 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2595802567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595802567?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA1HZTW8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2595780213","title":"ARS Pharmaceuticals - to Receive $4 Mln Regulatory Milestone and Is Eligible to Receive up to $80 Mln in Sales Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780213?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA1HZTW8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2595778043","title":"Neffy® (Epinephrine Nasal Spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595778043?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA1HZTW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2583068007","title":"ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583068007","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583068007?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:43","pubTimestamp":1763163801,"startTime":"0","endTime":"0","summary":"Justin Chakma, Chief Business Officer of ARS Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1Z85Gr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2583208509","title":"ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2583208509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583208509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:33","pubTimestamp":1763127184,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ0Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1189977586","title":"Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1189977586","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189977586?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778319,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. (NASDAQ: SPRY) saw its stock soar 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1113100917","title":"Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1113100917","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113100917?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778304,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock surged 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results, which showcased strong revenue growth and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2582982031","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2582982031","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582982031?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:11","pubTimestamp":1762773110,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582827210","title":"ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827210","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827210?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772450,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48746889/ars-pharmaceuticals-q3-eps-0-52-misses-0-47-estimate-sales-32-501m-beat-28-743m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2582449827","title":"ARS Pharmaceuticals Q3 Net Income USD -51.151 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582449827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582449827?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX59838A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}